Dr. Zain on Targets Under Investigation in T-Cell Lymphomas

Video

In Partnership With:

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses targets that are under investigation in T-cell lymphomas.

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses targets that are under investigation in T-cell lymphomas.

In the field of T-cell lymphoma, investigators are evaluating molecular signatures and expression with different types of gene chips to determine if there are certain pathways that can be targeted. Notably, TET2 and RHOA mutations are expressed in a subset of T-cell lymphomas and have become actionable targets with hypomethylating agents, says Zain.

Another target that has emerged is the epigenetic pathway. HDAC inhibitors have demonstrated efficacy in some T-cell lymphomas. For example, romidepsin (Istodax), vorinostat (Zolinza), and belinostat (Beleodaq) have shown response rates of approximately 30% in patients with relapsed peripheral T-cell lymphomas.

Combination strategies targeting the epigenetic pathway are also under evaluation. At City of Hope, the combination of lenalidomide (Revlimid) and romidepsin is being tested as frontline therapy in older patients who are ineligible for chemotherapy, concludes Zain.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD